Journal of Nuclear Medicine

Journal

Publication Venue For

  • Proceedings: Pathways for successful translation of new imaging agents and modalities—phase III studies.  60:736-744. 2019
  • Production of 15 O for medical applications via the 16 O(g,n) 15 O reaction.  60:424-428. 2019
  • Production and Use of the First-Row Transition Metal PET Radionuclides 43,44Sc, 52Mn, and 45Ti.  59:1655-1659. 2018
  • Imaging melphalan therapy response in preclinical extramedullary multiple myeloma with 18F-FDOPA and 18F-FDG PET.  59:1551-1557. 2018
  • ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body..  58:1174-1176. 2017
  • Noninvasive imaging of colitis using multispectral optoacoustic tomography.  58:1009-1012. 2017
  • Repeatability of 18F-FLT PET in a multicenter study of patients with high-grade glioma.  58:393-398. 2017
  • Characterizing the utility and limitations of repurposing an open-field optical imaging device for fluorescence-guided surgery in head and neck cancer patients.  58:246-251. 2017
  • A systematic approach for developing bacteria-specific imaging tracers.  58:144-150. 2017
  • PET/MRI of hypoxic atherosclerosis using 64Cu-ATSM in a rabbit model.  57:2006-2011. 2016
  • 18F-Fluciclovine (FACBC) and its potential use for breast cancer imaging.  57:1329-1330. 2016
  • Working Together to Advance Women in Nuclear Medicine..  57:14N. 2016
  • SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0..  57:1316-1322. 2016
  • Impact of MR-Based Attenuation Correction on Neurologic PET Studies..  57:913-917. 2016
  • Microfluidic preparation of a 89Zr-Labeled trastuzumab single-patient dose.  57:747-752. 2016
  • 2015 SNMMI highlights lecture: General nuclear medicine.  57:13N-18N. 2016
  • Pretargeted immuno-PET: Overcoming limitations of space and time.  57:332-333. 2016
  • MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy..  57:151-162. 2016
  • Successful translation of fluorescence navigation during oncologic surgery: A consensus report.  57:144-150. 2016
  • 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer.  56:1003-1010. 2015
  • American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain..  56:642-645. 2015
  • MIRD pamphlet No. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations.  55:1557-1564. 2014
  • Development of a radiolabeled irreversible peptide ligand for PET imaging of vascular endothelial growth factor.  55:1029-1034. 2014
  • Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma: Where antibody imaging dares to tread.  55:708-709. 2014
  • A standardized light-emitting diode device for photoimmunotherapy.  55:1893-1898. 2014
  • Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.  55:1636-1642. 2014
  • MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications.  54:2182-2188. 2013
  • Designing the magic bullet? the advancement of immuno-PET into clinical use.  54:1171-1174. 2013
  • 18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas..  54:1120-1126. 2013
  • PET with 18F-FDG-Labeled T lymphocytes for diagnosis of acute rat renal allograft rejection.  54:1147-1153. 2013
  • Radiolabeled amino acids for oncologic imaging..  54:1007-1010. 2013
  • A cross-sectional analysis of nuclear medicine technologists in the US concerning radiological emergency preparedness.  54. 2013
  • ABNM position statement: Nuclear medicine professional competency and scope of practice.  52:994-997. 2011
  • Components of a curriculum for molecular imaging scientists.  52:650-656. 2011
  • Potential of noninvasive serial assessment of acute renal allograft rejection by18F-FDG PET to monitor treatment efficiency.  51:1644-1652. 2010
  • MIRD pamphlet No. 22 (Abridged): Radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy.  51:311-328. 2010
  • Impact of rituximab treatment on 90Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.  51:150-157. 2010
  • Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.  50:2042-2048. 2009
  • MIRD dose estimate report No. 20: Radiation aBsorbed-dose estimates for 111In-And 90Y-ibritumomab Tiuxetan.  50:644-652. 2009
  • MIRD commentary: Proposed name for a dosimetry unit applicable to deterministic biological effects-the barendsen (Bd).  50:485-487. 2009
  • MIRD pamphlet No. 21: A generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature.  50:477-484. 2009
  • MIRD pamphlet no. 20: The effect of model assumptions on kidney dosimetry and response - Implications for radionuclide therapy.  49:1884-1899. 2008
  • A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae.  49:279-284. 2008
  • Diagnostic performance of an expert system for interpretation of 99mTc MAG3 scans in suspected renal obstruction.  49:216-224. 2008
  • Procedure guideline for SPECT/CT imaging 1.0.  47:1227-1234. 2006
  • Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0.  47:885-895. 2006
  • 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.  47:534-542. 2006
  • RENEX: An expert system for the interpretation of 99mTc-MAG3 scans to detect renal obstruction.  47:320-329. 2006
  • Imaging glioma extent with 131I-TM-601.  46:580-586. 2005
  • Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.  46:642-651. 2005
  • Concurrent PET/CT with an integrated imaging system: Intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance.  46:1225-1239. 2005
  • Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.  46:1034-1041. 2005
  • Reply [2].  46:1405-1406. 2005
  • Radiotargeted gene therapy.  46. 2005
  • Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multiinstitutional comparison.  45:1725-1733. 2004
  • Invited commentary: targeting of 125I-labeled B lymphocyte stimulator..  44:434-436. 2003
  • Targeting of 125I-labeled B lymphocyte stimulator.  44:434-436. 2003
  • Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting 90Y-antibody therapy.  43:1245-1253. 2002
  • A bayesian regression model for plasma clearance.  43:762-766. 2002
  • Metabolite production in patients with lymphoma after radiometal-labeled antibody administration.  42:1324-1333. 2001
  • Prediction of renal transplant survival from early postoperative radioisotope studies.  41:1332-1336. 2000
  • Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188Re.  41:887-895. 2000
  • Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.  41:952-958. 2000
  • A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for Non-Hodgkin's lymphoma.  40:2014-2020. 1999
  • Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.  40:2102-2106. 1999
  • Mouse models for internal radiation dosimetry [4] (multiple letters).  40:1969-1970. 1999
  • Factors affecting 131I-Lym-1 pharmacokinetics and radiationdosimetry in patients with non-Hodgkin's lymphoma and chroniclymphocytic leukemia.  40:1317-1326. 1999
  • Reproducibility of single-sample clearance of 99mTc- mercaptoacetyltriglycine and 131I-orthoiodohippurate.  40:1122-1124. 1999
  • 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma..  40:302-310. 1999
  • 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma.  40:302-310. 1999
  • Procedure guideline for diagnosis of renovascular hypertension.  39:1297-1302. 1998
  • A mouse bone marrow dosimetry model.  39:1243-1247. 1998
  • A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy.  39:1223-1229. 1998
  • Prediction of urinary excretion of technetium-99m-MAG3.  39:1257-1259. 1998
  • Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts.  39:842-849. 1998
  • Localization of idine-125-mIP-Des-Met14bmbesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer.  38:1221-1229. 1997
  • Radioimmunotherapy for breast cancer using indium-11 l/yttrium-90 BrE-3: Results of a phase i clinical trial.  38:1180-1185. 1997
  • Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources.  38:1374-1378. 1997
  • Exercise-rest same-day SPECT sestamibi imaging to detect coronary artery disease.  38:200-203. 1997
  • Fluorine-18-FPCT: A PET radiotracer for imaging dopamine transporters.  38:119-126. 1997
  • Gallium-67 Imaging of Pericardial Lymphoma in AIDS.  37:995-996. 1996
  • Myocardial Viability: Unresolved Issues.  37:794-797. 1996
  • Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.  37:1970-1975. 1996
  • Procedure guideline for general imaging: 1.0.  37:2087-2092. 1996
  • Procedure guideline for general imaging: 1.0. Society of Nuclear Medicine..  37:2087-2092. 1996
  • Consensus report on ACE inhibitor renography for detecting renovascular hypertension.  37:1876-1882. 1996
  • Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177- CC49.  37:1491-1496. 1996
  • Measurement of Renal Function with Technetium-99m-MAG3 in Children and Adults.  37:588-593. 1996
  • Accurate measurement of copper-67 in the presence of copper-64 contaminant using a dose calibrator.  37:302-306. 1996
  • Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy.  37:146-150. 1996
  • Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer.  36:2229-2233. 1995
  • Prediction of improvement in left ventricular function with iodine-123-IPPA after coronary revascularization..  36:1987-1993. 1995
  • Comparison of single-injection multisample renal clearance methods with and without urine collection.  36:603-606. 1995
  • Quantitative SPECT imaging: A review and recommendations by the focus committee of the society of nuclear medicine Computer and Instrumentation Council.  36:1489-1513. 1995
  • Renal clearance of technetium-99m-MAG3: Normal values [3].  36:706-708. 1995
  • Adenosine myocardial perfusion imaging.  35:734-736. 1994
  • Biokinetics of thallium-201 in normal subjects: Comparison between adenosine, dipyridamole, dobutamine and exercise.  35:535-541. 1994
  • Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung.  35:1381-1389. 1994
  • Quantitation of renal parenchymal retention of technetium-99m-MAG3 in renal transplants.  35:846-850. 1994
  • Sequential dual-isotope SPECT imaging with thallium-201 and technetium- 99m-sestamibi.  35:549-553. 1994
  • Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.  35:1017-1022. 1994
  • When is myocardial viability an important clinical issue?.  35. 1994
  • Indium-111-labeled polyclonal human immunoglobulin: Identifying focal infection in patients positive for human immunodeficiency virus.  34:1621-1625. 1993
  • Thallium reinjection imaging: The search for an optimal protocol.  34:743-746. 1993
  • Comparison of same-day protocols using technetium-99m-sestamibi myocardial imaging.  33:186-191. 1992
  • Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer.  33:1648-1653. 1992
  • Early thallium imaging after percutaneous transluminal coronary angioplasty: Tomographic evaluation during adenosine-induced coronary hyperemia.  33:2086-2089. 1992
  • Mean time parameters reveal differences in the pharmacokinetics of indium- 111 and iodine-131-labeled B72.3 monoclonal antibody.  33:2248-2250. 1992
  • Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer.  33:23-29. 1992
  • Renal transplant hypertension caused by iliac artery stenosis.  33:1178-1180. 1992
  • Editorial: Is redistribution important in sestamibi myocardial imaging?.  32:1966-1967. 1991
  • Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody.  32:1162-1168. 1991
  • Quantitation of renal function using MAG3.  32:2061-2063. 1991
  • Simplified methods for renal clearance in children: Scaling for patient size.  32:1821-1825. 1991
  • Measurement of renal function with radionuclides.  30:2053-2057. 1989
  • Quantitation of renal function with technetium-99m MAG3.  29:1931-1933. 1988
  • Abnormal captopril renogram with a technetium-99m-labeled hippuran analog.  29:1730-1737. 1988
  • Comparison of technetium-99m MAG3 with iodine-131 hippuran by a simultaneous dual channel technique.  29:1189-1193. 1988
  • Estimation of extracellular fluid volume from plasma clearance on Technetium-99m DTPA by a single-injection, two-sample method.  29:255-258. 1988
  • Uncontrolled variables in the measurement of renal function..  27:1644. 1986
  • Gates method for GFR measurement..  27:1373-1374. 1986
  • Measurement of glomerular filtration rate: Single injection plasma clearance method without urine collection.  26:1243-1247. 1985
  • Gallium-67 scanning in Sjogren's syndrome: Concise communication.  25:299-302. 1984
  • Quality control of Tc-99m DTPA for measurement of glomerular filtration: concise communication.  24:722-727. 1983
  • Localization of radiolabeled mouse alloantibody in a sarcoma induced by 3-methylcholanthrene.  21:77-80. 1980
  • Use of blood-pool imaging in evaluation of diffuse activity patterns in technetium-99m pyrophosphate myocardial scintigraphy.  20:496-501. 1979
  • Comprehensive evaluation of renal function in the transplanted kidney.  16:1115-1120. 1975
  • Demonstration of a chemodectoma by perfusion scanning: case report.  16:472-473. 1975
  • Use of 99mTc as a radioisotopic label to study the migratory patterns of normal and neoplastic cells.  15:656-661. 1974
  • Labeling of mammalian nucleated cells with (99m)Tc.  14:706-708. 1973
  • Pancreatic visualization with 75 Se-selenomethionine after surgery..  13:765-766. 1972
  • International Standard Serial Number (issn)

  • 0161-5505
  • Electronic International Standard Serial Number (eissn)

  • 1535-5667
  • 2159-662X